MedTrace Logo

Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers

NCT04092712 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-09-25

No results posted yet for this study

Summary

This study will assess the absorption, metabolism, excretion, mass balance, safety, and tolerability of a single oral administration of \[14C\]-CTP-543 in healthy male subjects.

Conditions

  • Healthy Volunteers

Interventions

DRUG

[14C]-CTP-543

Single dose of radiolabeled CTP-543 (approximately 75 μCi) administered as an oral solution

Sponsors & Collaborators

  • Celerion

    collaborator INDUSTRY

  • Concert Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-05
Primary Completion
2019-09-11
Completion
2019-09-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04092712 on ClinicalTrials.gov